Abstract
AbstractNowadays, selective estrogen receptor modulators (SERMs) and downregulators (SERDs) are used as the first‐line medical treatment for estrogen receptor positive (ER+) tumors. Herein we report synthesis, ER‐α binding activity, and cytotoxicity of LSZ102 selenium analogues 11 and 28. TR‐FRET competitive ER‐α binding experiments and cytotoxicity assays have shown that the selenium analogues exhibit closely related activity to LSZ102. Furthermore, the prepared selenium analogues are not toxic in rat cardiomyoblasts (H9C2), indicating that substituted benzo[b]selenophene is a prospective scaffold for the development of ER‐α modulators and downregulators for the treatment of ER+ cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
